Fresenius Kabi announced that the Food and Drug Administration (FDA) has approved the launch of Naropin (ropivacaine HCl) 2% injection in the company’s Freeflex delivery system.

Naropin is an amide-type local anesthetic indicated for the production of local or regional anesthesia for surgery (epidural block including cesarean section, major nerve block, local infiltration) and for acute pain management (epidural continuous infusion or intermittent bolus, eg, postop or labor; local infiltration).

RELATED: Unique 3-Chamber Parenteral Nutrition Bag Approved

The Freeflex container contains a non-PVC and non-DEHP multilayer polyolefin film for convenience and improved safety. The proprietary design provides clinicians with more choices in treating patients that need continuous epidural infusions or local infiltration.

Naropin is available as a 0.2% strength in 100mL and 200mL premix bags. Naropin is already available in various single-dose vials, plastic ampule sterile-paks, and infusion bottle formulations in 0.5%, 0.75%, and 1% strengths.

For more information call (888) 386-1300 or visit